Co-delivery of IL-12/IL-15/IL-18 engineered DC vaccines with anti-IL-10R and nanoconjugated methotrexate in melanoma

Modified dendritic cells, which carry proinflammatory cytokines, were used in immuno- and chemoimmunotherapeutic experiments. The developed therapies effectively inhibited tumor growth, but the rate of tumor growth depended on the type of vaccine used. Incorporating the nanoconjugate prior to immunological treatment primarily reduced the population of suppressor cells. The most effective treatment was observed in two cases: as a result of immunotherapy including the use of a two-component vaccine DC/IL-12/TAg + DC/IL-18/TAg (TGI 62.3%) or after administration of HES-MTX nanoconjugate followed by immunotherapy with three-component vaccine - DC/IL-12/TAg + DC/IL-15/IL-15Rα/TAg + DC/IL-18/TAg (TGI 59.1%).